Fluticasione furoate / vilanterol combination (Relvar Ellipta®) in bronchial asthma: a review of clinical trials
https://doi.org/10.18093/0869-0189-2015-25-5-622-627
Abstract
This review has summarized clinical trials data on efficacy and safety of new combination of inhaled steroid fluticasione furoate (FF) and longacting beta2agonist vilanterol in patients with bronchial asthma. Treatment with this combination could effectively reduce a risk and frequency of severe asthma exacerbations, improve lung function, quality of life and control of asthma, improve asthma symptoms and need in relief medications, increase number of days without asthma symptoms and without use of asneeded bronchodilators. This combination was equally effective being administered both in the morning and in the evening that, in turn, allowed the most convenient treatment regimen for the patient and could additionally improve control of the disease. Tolerability of the FF / vilanterol combination is similar to that of placebo. The FF / vilanterol combination is delivered via a new inhalation device Ellipta® which is ease and convenient to use.
About the Author
S. Yu. Chikina
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia: 32, build. 4, 11th Parkovaya str., Moscow, 105077, Russia
Russian Federation
Russian Federation
PhD, Senior Researcher at Laboratory of Functional and Ultrasound Investigations; Federal Institution «Pulmonology Research Institute», Federal Medical and Biological Agency of
Russia; tel.: (495) 9677744
References
1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2015.
2. Cazzola M., Matera M.G. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 2009; 34: 757–769.
3. Biggadike K., Bledsoe R.K., Hassell A.M. et al. Xray crystal structure of the novel enhancedaffinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptorligand binding domain. J. Med. Chem. 2008; 51 (12): 3349–3352.
4. Allen A., Schenkenberger I., Trivedi R. et al. Inhaled fluticasone furoate / vilanterol does not affect hypothalamic pituitaryadrenal axis function in adolescent and adult asthma: randomised, doubleblind, placebocontrolled study. Clin. Respir. J. 2013; 7 (4): 397–406.
5. Oliver A., Bjermer L., Quinn D. et al. Modulation of aller geninduced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 2013; 68 (9):1136–1142.
6. Bleecker E.R., Lötvall J., O'Byrne P.M. et al. Fluticasone furoatevilanterol 100–25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J. Allergy Clin. Immunol. Pract. 2014; 2 (5): 553–561.
7. Bateman E.D., O'Byrne P.M., Busse W.W. et al. Oncedaily fluticasone furoate (FF) / vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014; 69 (4): 312–319.
8. O'Byrne P.M., Bleecker E.R., Bateman E.D. et al. Once daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur. Respir. J. 2014; 43 (3): 773–782.
9. Kempsford R.D., Oliver A., Bal J. et al. The efficacy of oncedaily fluticasone furoate / vilanterol in asthma is comparable with morning or evening dosing. Respir. Med. 2013; 107 (12): 1873–1880.
10. Woodcock A., Bateman E.D., Busse W.W. et al. Efficacy in asthma of oncedaily treatment with fluticasone furoate: a randomized, placebocontrolled trial. Respir. Res. 2011; 12: 132.
11. Busse W.W., Bleecker E.R., Bateman E.D. et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8week, randomised, placebocontrolled trial. Thorax. 2012; 67 (1): 35–41.
12. Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1331.
13. Svedsater H., Jacques L., Goldfrad C., Bleecker E.R. Ease of use of the Ellipta dry powder inhaler: data from three randomized controlled trials in patients with asthma. Primary Care Respir. Med. 2014; 24: 14019. DOI: 10.1038/npjpcrm. 2014.19.
14. Sharma R., Komase Y., Akimoto A., Kobayashi A. Operability of the ElliptaTM dry powder inhaler: a comparative evaluation of handling technique in inhalation therapynaїve subjects. Am. J. Respir. Crit. Care Med. 2014; 189: A5693.
Review
For citations:
Chikina S.Yu. Fluticasione furoate / vilanterol combination (Relvar Ellipta®) in bronchial asthma: a review of clinical trials. PULMONOLOGIYA. 2015;25(5):622-627. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-5-622-627
Views:
5971
Email this article 